The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple Negative Breast Cancer by Attenuating TGFβ Signaling.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
13 Aug 2024
Historique:
accepted: 08 08 2024
received: 07 12 2023
revised: 03 06 2024
medline: 13 8 2024
pubmed: 13 8 2024
entrez: 13 8 2024
Statut: aheadofprint

Résumé

The pogo transposable element derived zinc finger protein, POGZ, is notably associated with neurodevelopmental disorders through its role in gene transcription. Many proteins involved in neurological development are often dysregulated in cancer, suggesting a potential role for POGZ in tumor biology. Here, we provided experimental evidence that POGZ influences the growth and metastatic spread of triple negative breast cancers (TNBC). In well-characterized models of TNBC, POGZ exerted a dual role, both as a tumor promoter and metastasis suppressor. Mechanistically, loss of POGZ potentiated TGFβ pathway activation to exert cytostatic effects while simultaneously increasing the mesenchymal and migratory properties of breast tumors. Whereas POGZ levels are elevated in human breast cancers, the most aggressive forms of TNBC tumors, including those with increased mesenchymal and metastatic properties, exhibit dampened POGZ levels, and low POGZ expression was associated with inferior clinical outcomes in these tumor types. Taken together, these data suggest that POGZ is a critical suppressor of the early stages of the metastatic cascade.

Identifiants

pubmed: 39137399
pii: 746976
doi: 10.1158/0008-5472.CAN-23-3887
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

John Heath (J)

McGill University, Montreal, Quebec, Canada.

Caitlynn Mirabelli (C)

McGill University, Montreal, Quebec, Canada.

Matthew G Annis (MG)

McGill University, Montreal, Quebec, Canada.

Valerie Sabourin (V)

Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Steven Hébert (S)

Jewish General Hospital, Montreal, Quebec, Canada.

Steven Findlay (S)

McGill University, Montreal, Quebec, Canada.

HaEun Kim (H)

McGill University, Montreal, Quebec, Canada.

Michael Witcher (M)

Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montréal, QC, Canada.

Claudia L Kleinman (CL)

McGill University, Montreal, QC, Canada.

Peter M Siegel (PM)

McGill University, Montreal, Quebec, Canada.

Alexandre Orthwein (A)

Emory University, Atlanta, GA, United States.

Josie Ursini-Siegel (J)

McGill University, Montreal, Quebec, Canada.

Classifications MeSH